Nonacus, a leading provider of innovative genomics solutions worldwide, is proud to announce that Jeff Bousfield has been appointed as the new Chief Executive Officer, effective immediately. This appointment reflects Nonacus’ confidence in the next phase of its expansion and positions the company for even greater success in the future.
An accomplished leader, Jeff joined Nonacus in December 2023 as Chief Financial Officer, bringing a proven track record of driving growth and innovation. Previous appointments include Chief Operating Officer of Distributed, leading the company to recognition as the UK's leading technology talent cloud, following on from appointments as Chief Financial Officer of City-based investment management organisations and 5 years at GSK in positions of increasing seniority.
Jeff expressed his enthusiasm for his new role, stating,
“Nonacus is solving problems that’ll improve the lives of billions worldwide through the universal availability of early cancer diagnosis, detection and management. I'm honored to lead this amazing team that has already achieved so much. Together, we will continue to innovate and deliver groundbreaking solutions that transform patient care and advance the future of precision medicine, focusing on improving patient outcomes and making a meaningful difference to people's lives.”
Jeff succeeds Chris Sale, who successfully co-founded and led Nonacus through a decade of remarkable growth and innovation. Chris will transition to Chief Commercial Officer, where he will leverage his extensive 24-year experience in building strong customer relationships and implementing commercial strategy. This move allows Chris to fully focus on Nonacus’ ambitious growth plans by fostering deep connections with customers, collaborating with industry-leading innovators and leading the conversation on utilizing advanced genomics technology in the healthcare industry.
Chris commented on the transition,
"It has been an incredible privilege to lead Nonacus to this point and work alongside such an exceptionally talented team. I am excited to return to a customer-facing role, as I've truly missed the relationships with our labs and the innovation we can drive together—they have always been a source of energy and inspiration for me. I have full confidence that under Jeff’s leadership, Nonacus will achieve its ambitious goals”.
Co-founder and Chief Product Officer, Lee Silcock, adds,
"Reflecting on our journey since our founding in 2015, and approaching our 10th anniversary in 2025, it's truly remarkable to see how far we've come and the successes we've achieved. I’m delighted to welcome Jeff as our new CEO – his scaling experience and commercial focus make him a great fit for Nonacus. Chris's dedication to this company has been exemplary, and I'm confident his new role as Chief Commercial Officer will allow him to excel in what he does best—building strong customer relationships and innovating with our partners. By enabling Chris to lead our commercial growth and with Jeff at the helm, I'm incredibly excited for the future of Nonacus and our ongoing mission to innovate and enhance patient care."
Want to learn more about who we are and what we do?
Visit our About us page for further information.
